Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years

Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.